RPHM Stock Price, Reneo Pharmaceuticals, . Quote, Chart

Market Summary

USD1.73+0.02

Market Closed

1.17%

RPHM Stock Price

View Fullscreen

RPHM RSI Chart

RPHM Valuation

Market Cap

57.8M

Price/Earnings (Trailing)

-0.75

Price/Free Cashflow

-0.9

RPHM Price/Earnings (Trailing)

RPHM Profitability

Return on Equity

-87.34%

Return on Assets

-72.03%

Free Cashflow Yield

-110.52%

RPHM Fundamentals

RPHM Earnings

Earnings (TTM)

-77.4M

Earnings Growth (Yr)

-73.19%

Earnings Growth (Qtr)

-22.7%

Breaking Down RPHM Revenue

Last 7 days

4.9%

Last 30 days

1.2%

Last 90 days

8.8%

Trailing 12 Months

-82.5%

How does RPHM drawdown profile look like?

RPHM Financial Health

Current Ratio

5.87

RPHM Investor Care

Buy Backs (1Y)

0.70%

Diluted EPS (TTM)

-2.53

Tracking the Latest Insider Buys and Sells of Reneo Pharmaceuticals, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Aug 28, 2023	hall ashley	acquired	28,125	1.8	15,625	chief development officer
Aug 28, 2023	hall ashley	sold	-98,057	6.2757	-15,625	chief development officer
Jul 26, 2023	grey michael g	gifted	-	-	-50,000	executive chairman
Jun 23, 2023	novo holdings a/s	sold	-709,740	7.0974	-100,000	-
May 08, 2023	o'donnell niall	bought	1,000,000	8.00	125,000	-
Sep 01, 2022	cruse michael	bought	25,447	3.393	7,500	chief operating officer
Aug 31, 2022	grey michael g	acquired	98,500	1.97	50,000	executive chairman
Aug 31, 2022	cruse michael	bought	10,307	3.209	3,212	chief operating officer
Aug 30, 2022	cruse michael	bought	5,892	3.1938	1,845	chief operating officer
Aug 30, 2022	cruse michael	bought	3,081	3.16	975	chief operating officer

Which funds bought or sold RPHM recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
Apr 30, 2024	Avior Wealth Management, LLC	new	-	3.00	3.00	-%
Apr 30, 2024	Private Wealth Management Group, LLC	new	-	1,363	1,363	-%
Apr 29, 2024	China Universal Asset Management Co., Ltd.	added	65.66	5,000	11,000	-%
Apr 29, 2024	COMMONWEALTH EQUITY SERVICES, LLC	unchanged	-	1,000	32,000	-%
Apr 25, 2024	Bank of New York Mellon Corp	reduced	-22.21	-13,579	56,815	-%
Apr 24, 2024	BML Capital Management, LLC	added	65.72	1,512,570	3,615,340	2.38%
Apr 23, 2024	AMALGAMATED BANK	reduced	-72.47	-1,000	1,000	-%
Mar 11, 2024	VANGUARD GROUP INC	added	0.38	-5,859,520	1,566,220	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	added	206	-114,882	207,316	-%

Are Funds Buying or Selling RPHM?

Are funds buying RPHM calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own RPHM

No. of Funds

Unveiling Reneo Pharmaceuticals, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 05, 2024	octagon capital advisors lp	6.75%	2,250,000	SC 13G
Jan 17, 2024	bml investment partners, l.p.	4.1%	1,364,229	SC 13G
Dec 26, 2023	tang capital partners lp	996%	3,330,000	SC 13D
Dec 15, 2023	novo holdings a/s	0%	0	SC 13D/A
May 30, 2023	rivervest venture fund iii, l.p.	0.97%	328,094	SC 13D/A
May 15, 2023	novo holdings a/s	10.2%	3,430,377	SC 13D/A
May 09, 2023	carlyle group inc.	8.2%	2,730,457	SC 13D/A

Recent SEC filings of Reneo Pharmaceuticals, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 26, 2024	10-K/A	Annual Report
Mar 28, 2024	S-8	Employee Benefits Plan
Mar 28, 2024	8-K	Current Report
Mar 28, 2024	10-K	Annual Report
Feb 23, 2024	8-K	Current Report
Feb 05, 2024	SC 13G	Major Ownership Report

Peers (Alternatives to Reneo Pharmaceuticals, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	48.1B	6.8B	21.21%	-3.50%	-8.06	7.03	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.0B	2.0B	-0.48%	-24.66%	-57.25	9.49	75.20%	68.82%
BMRN	15.9B	2.5B	-3.50%	-10.49%	77.41	6.43	13.74%	186.89%
INCY	11.9B	3.8B	-4.91%	-21.97%	15.99	3.16	8.58%	129.81%
MID-CAP
APLS	5.7B	396.6M	-14.74%	-44.14%	-10.83	14.44	425.83%	18.94%
BBIO	5.2B	107.9M	-3.68%	92.64%	-9.5	48.09	54.84%	-28.31%
AXSM	3.5B	270.6M	-0.50%	3.10%	-14.69	12.99	440.80%	-27.84%
ARWR	3.0B	240.7M	-7.87%	-39.98%	-10.07	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-5.69%	-19.43%	-45.92	3.87	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-1.57%	-9.52%	24.79	4.45	85.90%	-14.05%
NVAX	659.2M	983.7M	3.97%	-34.13%	-1.21	0.67	-50.36%	17.16%
CRBP	400.8M	881.7K	1.98%	349.41%	-8.99	466.16	-77.61%	-5.33%
INO	280.7M	4.9M	-3.22%	25.10%	-2.08	57.68	-54.97%	51.71%
IBIO	7.0M	2.1M	-29.72%	84.40%	-0.26	2.14	-13.45%	66.37%

Reneo Pharmaceuticals, Inc. News

Latest updates

Reneo Pharmaceuticals, Inc. Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet													(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4
Assets	-17.6%	107	130	148	99.00	108	123	134	144	154	163	171	95.00	55.00
Current Assets	-17.2%	107	129	146	97.00	106	121	132	143	154	163	171	94.00	55.00
Cash Equivalents	135.4%	28.00	12.00	9.00	30.00	20.00	62.00	118	121	125	126	140	91.00	54.00
Net PPE	-74.7%	0.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Liabilities	21.9%	19.00	15.00	16.00	12.00	8.00	10.00	9.00	9.00	7.00	7.00	4.00	4.00	5.00
Current Liabilities	34.0%	18.00	14.00	14.00	10.00	7.00	9.00	8.00	8.00	6.00	6.00	3.00	4.00	5.00
Shareholder's Equity	-22.9%	89.00	115	133	87.00	100	112	124	135	147	156	168	-	-
Retained Earnings	-14.7%	-218	-190	-171	-151	-136	-123	-110	-97.76	-84.73	-74.10	-61.40	-97.80	-44.96
Additional Paid-In Capital	0.5%	307	305	304	239	237	235	234	233	232	230	229	3.00	3.00
Shares Outstanding	-1.3%	33.00	34.00	34.00	25.00	25.00	24.00	24.00	24.00	24.00	24.00	21.00	2.00	2.00
Float	-	-	-	151	-	-	-	39.00	-	-	-	93.00	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1
Cashflow From Operations	-5.8%	-19,782	-18,700	-16,200	-9,000	-15,613	-10,794	-11,956	-8,999	-10,021	-9,672	-9,701	-8,589	-5,411	-5,741	-2,937	-4,447
Share Based Compensation	-7.7%	1,319	1,429	1,207	1,157	1,217	990	1,006	1,107	1,421	1,145	854	471	129	84.00	88.00	92.00
Cashflow From Investing	87.2%	39,776	21,250	-69,011	18,507	-26,917	-45,435	9,083	5,427	8,153	-4,509	-26,995	-25.00	-16.00	1,193	1,000	5,199
Cashflow From Financing	-2486.1%	-4,128	173	63,811	1,009	325	97.00	43.00	6.00	119	222	85,843	46,222	47,195	51.00	-	26.00

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

RPHM Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating expenses:
Research and development	$ 56,613	$ 37,705
General and administrative	26,440	16,143
Total operating expenses	83,053	53,848
Loss from operations	(83,053)	(53,848)
Other income:
Other income	5,665	1,893
Net loss	(77,388)	(51,955)
Unrealized gain (loss) on short-term investments	51	(77)
Comprehensive loss	$ (77,337)	$ (52,032)
Net loss per share attributable to common stockholders, basic	$ (2.52)	$ (2.12)
Net loss per share attributable to common stockholders, diluted	$ (2.52)	$ (2.12)
Weighted-average shares used in computing net loss per share, basic	30,676,455	24,496,425
Weighted-average shares used in computing net loss per share, diluted	30,676,455	24,496,425

RPHM Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 27,632	$ 19,927
Short-term investments	75,331	81,246
Prepaid expenses and other current assets	3,659	5,180
Total current assets	106,622	106,353
Property and equipment, net	134	453
Right-of-use assets	599	1,292
Other non-current assets	81	84
Total assets	107,436	108,182
Current liabilities:
Accounts payable	8,717	1,893
Accrued expenses	9,129	4,827
Operating lease liabilities, current portion	331	404
Total current liabilities	18,177	7,124
Operating lease liabilities, less current portion	642	1,059
Performance award	7	29
Total liabilities	18,826	8,212
Stockholders' equity (deficit):
Common stock, $0.0001 par value; 200,000,000 shares authorized at December 31, 2022 and December 31, 2021; 24,699,553 shares issued and outstanding at December 31, 2022; and 24,457,838 and 24,455,390 shares issued and outstanding at December 31, 2021, respectively	3	3
Additional paid-in capital	307,073	236,693
Accumulated deficit	(218,474)	(136,683)
Accumulated other comprehensive (loss) income	8	(43)
Total stockholders' equity	88,610	99,970
Total liabilities and stockholders' equity	$ 107,436	$ 108,182

About Reneo Pharmaceuticals, Inc.

Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. Its lead product candidate is REN001, a potent and selective agonist of the peroxisome proliferator-activated receptor delta that is in clinical development for genetic mitochondrial diseases comprising primary mitochondrial myopathies and long-chain fatty acid oxidation disorders. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Irvine, California.

CEO	Mr. Gregory J. Flesher
WEBSITE	https://reneopharma.com
INDUSTRY	Biotechnology
EMPLOYEES	51

Reneo Pharmaceuticals, Inc. Frequently Asked Questions

What is the ticker symbol for Reneo Pharmaceuticals, Inc.? What does RPHM stand for in stocks?

RPHM is the stock ticker symbol of Reneo Pharmaceuticals, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Reneo Pharmaceuticals, Inc. (RPHM)?

As of Thu May 02 2024, market cap of Reneo Pharmaceuticals, Inc. is 57.82 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of RPHM stock?

You can check RPHM's fair value in chart for subscribers.

What is the fair value of RPHM stock?

You can check RPHM's fair value in chart for subscribers. The fair value of Reneo Pharmaceuticals, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Reneo Pharmaceuticals, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for RPHM so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Reneo Pharmaceuticals, Inc. a good stock to buy?

The fair value guage provides a quick view whether RPHM is over valued or under valued. Whether Reneo Pharmaceuticals, Inc. is cheap or expensive depends on the assumptions which impact Reneo Pharmaceuticals, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RPHM.